AUD10.17
0.99% today
Australia, Jun 26, 08:00 am CET
ISIN
AU000000CUV3
Symbol
CUV
Sector
Industry

Clinuvel Pharmaceutical Stock price

AUD10.19
-0.24 2.30% 1M
-1.96 16.13% 6M
-1.87 15.51% YTD
-5.14 33.53% 1Y
-5.81 36.31% 3Y
-15.38 60.15% 5Y
+7.28 249.61% 10Y
+6.79 199.45% 20Y
Australia, Closing price Thu, Jun 26 2025
+0.12 1.19%
ISIN
AU000000CUV3
Symbol
CUV
Sector
Industry

Key metrics

Basic
Market capitalization
AUD502.2m
Enterprise Value
AUD304.7m
Net debt
AUD-197.5m
Cash
AUD198.2m
Shares outstanding
50.1m
Valuation (TTM | estimate)
P/E
13.08 | -
P/S
5.26 | 5.01
EV/Sales
3.19 | 3.04
EV/FCF
12.97
P/B
2.32
Dividends
DPS
AUD0.08
Yield 1Y | 5Y
0.76% | 0.26%
Growth 1Y | 5Y
0.00% | 14.87%
Payout 1Y | 3Y
11.00% | 12.75%
Increased
0 Years
Financials (TTM | estimate)
Revenue
AUD95.4m | AUD100.3m
EBITDA
AUD56.5m | AUD51.7m
EBIT
AUD55.3m
Net Income
AUD38.8m | -
Free Cash Flow
AUD23.5m
Growth (TTM | estimate)
Revenue
9.29% | 5.03%
EBITDA
9.01% | -8.42%
EBIT
8.81%
Net Income
28.62% | -
Free Cash Flow
-35.34%
Margin (TTM | estimate)
Gross
96.70%
EBITDA
59.22% | 51.56%
EBIT
57.98%
Net
40.65% | -
Free Cash Flow
24.63%
Financial Health
Equity Ratio
87.84%
Return on Equity
17.55%
ROCE
24.79%
ROIC
146.84%
Debt/Equity
0.00
More
EPS
AUD0.77
FCF per Share
AUD0.47
Short interest
-
Employees
16.00
Rev per Employee
AUD5.97m
Show more

Is Clinuvel Pharmaceutical a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,912 stocks worldwide.

Clinuvel Pharmaceutical Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Clinuvel Pharmaceutical forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a Clinuvel Pharmaceutical forecast:

Buy
100%

Financial data from Clinuvel Pharmaceutical

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
95 95
9% 9%
100%
- Direct Costs 3.15 3.15
139% 139%
3%
92 92
3% 3%
97%
- Selling and Administrative Expenses 32 32
26% 26%
33%
- Research and Development Expense 4.44 4.44
210% 210%
5%
56 56
9% 9%
59%
- Depreciation and Amortization 1.17 1.17
18% 18%
1%
EBIT (Operating Income) EBIT 55 55
9% 9%
58%
Net Profit 39 39
29% 29%
41%

In millions AUD.

Don't miss a Thing! We will send you all news about Clinuvel Pharmaceutical directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Clinuvel Pharmaceuticals Ltd. operates as a biopharmaceutical company. The firm engages in the development of SCENESSE, its proprietary photoprotective drug. It also offers drugs for the treatment of various skin disorders. The company was founded by Robert Thomas Dorr on December 14, 1999 and is headquartered in Melbourne, Australia.

Head office Australia
CEO Lachlan Hay
Employees 16
Founded 1999
Website www.clinuvel.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today